Aravive Highlights Updated Batiraxcept Data From Kidney Cancer Trial


Aravive Inc ARAV has announced new data from the Phase 1b portion of the ongoing Phase 1b/2 trial of batiraxcept in clear cell renal cell cancer (ccRCC).

  • 26 previously treated ccRCC patients have been treated with batiraxcept at doses of 15 mg/kg (n=16) and 20 mg/kg (n=10), plus cabozantinib 60 mg.
  • No dose-limiting toxicities were observed at either the 15 mg/kg or 20 mg/kg batiraxcept dose combined with cabozantinib.
  • At a median follow-up of 4.9 months, 92% of patients remain on study.
  • Best overall response rate (ORR) in the ITT population is 46% (12/26), with 56% at 15 mg/kg and 30% at 20 mg/kg
  • The 6-month progression-free survival (PFS) rate in the ITT population is 79%
  • The median duration of response (DOR) has not been reached; the 3-month DOR is 100%
  • The best ORR was 63% in the biomarker high population, with a 6-month PFS rate of 77%.
  • Price Action: ARAV shares are 6.86% at $2.25 during the market session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefsKidney Cancer
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!